共 50 条
Novel nonsymmetrically benzimidazolium salts and their silver (I)-N-heterocyclic carbene complexes: Synthesis, DFT study and Anticancer activities
被引:1
|作者:
Rahali, Emna
[1
]
Boubakri, Lamia
[2
]
Gurbuz, Nevin
[3
,4
]
Ozdemir, Ismail
[3
,4
]
Mansour, Lamjed
[5
]
Arfaoui, Youssef
[1
]
Sauthier, Mathieu
[6
]
Hamdi, Naceur
[2
]
机构:
[1] Univ Tunis El Manar, Dept Chem, Lab Characterizat Applicat & Modeling Mat, LR18ES08, Tunis 1068, Tunisia
[2] Univ Carthage, Higher Inst Environm Sci & Technol, Res Lab Environm Sci & Technol, LR16ES09, Hammam Lif, Tunisia
[3] Inonu Univ, Catalyst Res & Applicat Ctr, TR-44280 Malatya, Turkiye
[4] Inonu Univ Drug Applicat & Res Ctr, TR-44280 Malatya, Turkiye
[5] King Saud Univ, Coll Sci, Zool Dept, POB 2455, Riyadh 11451, Saudi Arabia
[6] USTL, Ecole Natl Super Chim Lille, Unite Catalyse & Chim Solide, UMR CNRS 8181, BP 90108, F-59652 Villeneuve dAscq, France
关键词:
Anticancer activity;
6-dimethylbenzimidazole;
N -Heterocyclic carbene;
Silver complexes;
N-HETEROCYCLIC CARBENES;
METAL-COMPLEXES;
P-NITROBENZYL;
ANTIBACTERIAL;
D O I:
10.1016/j.molstruc.2024.139947
中图分类号:
O64 [物理化学(理论化学)、化学物理学];
学科分类号:
070304 ;
081704 ;
摘要:
A series of unsymmetrically substituted N-heterocyclic carbene (NHC) precursors were synthesized from the action of 5,6-dimethylbenzimidazole or benzimidazole with various alkyl halides in DMF at 80 degrees C for 72 h . These compounds were used to synthesize NHC-silver(I) complexes (3) by reacting these NHC precursors with Ag2O in DMC.The prepared compounds were structurally verified by several spectroscopic techniques including 1H NMR, 13C NMR, FT-IR, LC-MS, and C, H, N analysis. The structures of the NHC precursors and their corresponding silver(I) complexes were also investigated theoretically using density functional theory (DFT) at the BLYP/TZ2P level to optimize geometries and assess electronic properties via Voronoi Deformation Density (VDD) charge analysis. Additionally, the newly synthesized ligands and silver(I) complexes were evaluated for their in vitro anticancer activity against three human cancer cell lines including hepatocellular carcinoma (HePG2), lung adenocarcinoma (A549) and breast adenocarcinoma (MCF7). Most of the newly synthesized silver(I) complexes exhibited better activity than the ligands, and the results have been compared with Cisplatin as a reference drug.
引用
收藏
页数:11
相关论文